Brief: Rezolute Says Preclinical Pharmacology Study Validates Potential Use Of RZ358 For Treatment Of Non-Islet Cell Tumor Hypoglycemia
06/03/2024 12:33
March 6 (Reuters) - Rezolute Inc RZLT.O :
* REZOLUTE REPORTS VALIDATION OF THE POTENTIAL USE OF RZ358
FOR
TREATMENT OF NON-ISLET CELL TUMOR HYPOGLYCEMIA (NICTH)
Source text for Eikon: ID:nGNXbcz67G
Further company coverage: RZLT.O
((Reuters.Briefs@thomsonreuters.com;))